NewsBenzingaPepGen annuncia che i dati del suo studio di fase 2 FREEDOM2-DM1 su PGN-EDODM1 dimostrano una correzione media dello splicing del 46,5%; PGN-EDODM1 ha mostrato un’elevata tollerabilità; PepGen annuncia che i dati del suo studio di fase 2 FREEDOM2-DM1 su PGN-EDODM1 dimostrano una correzione media dello splicing del 46,5%; PGN-EDODM1 ha mostrato un’elevata tollerabilità; Benzinga 2026.11.10 12:07 (GMT+0) Open on Benzinga Other news Keybanc Reiterates Sector Weight on NVIDIAto Sector Weight Top 3 Tech Stocks That May Fall Off A Cliff This Month Truist Securities Maintains Hold on BILL Holdings, Raises Price Target to $66 Nvidia’s China Exit Could Trigger a Bull-Bear Showdown: 6 Leveraged ETFs to Watch Wednesday OTraces Selects Labcorp To Perform Reference Laboratory Testing For Florida Department Of Health–Funded Clinical Trial Evaluating OTraces Blood-Based Prostate Cancer Diagnostic Platform Quanterix Affirms FY2026 Sales Guidance of $142.000M-$146.000M vs $143.357M Est
OTraces Selects Labcorp To Perform Reference Laboratory Testing For Florida Department Of Health–Funded Clinical Trial Evaluating OTraces Blood-Based Prostate Cancer Diagnostic Platform